Form 4: Biogen Director Jesus B. Mantas Receives Stock Grant

Biogen Inc. director Jesus B. Mantas acquired 1,505 restricted stock units as part of an equity compensation grant.

Summary

• Director Jesus B. Mantas was granted 1,505 restricted stock units (RSUs) on June 9, 2026.
• The grant was issued at a price of $0 per share, representing standard equity compensation.
• Following this transaction, the total number of shares beneficially owned by the director is 11,263.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• The transaction reflects standard director compensation alignment with shareholder interests.

Negatives

• None.

Risks

• None.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 9, 2027).

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director equity compensation, which is standard practice for large-cap biotechnology firms to ensure board member alignment with long-term corporate performance.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with compensation structures at peer companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity grant.

Next Steps

• Vesting of the 1,505 restricted stock units upon the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Form 4, Insider Trading, Director Compensation, Equity Grant